Fluor is providing architectural and engineering services and procuring equipment for the new 275,000 square-foot manufacturing facility that will house two manufacturing lines to double manufacturing capability
The investment enhances Lonza’s capabilities and flexibility to support both clinical and commercial supply and will play a key role in meeting the growing market demand for bioconjugates
The company has reported total income of Rs.129.14 crores during the period ended December 31, 2022 as compared to Rs.157.54 crores during the period ended December 31, 2021.
Strategic partnership aims to support significant growth of the Ibuprofen product market in Brazil and is backed by Univar Solutions' state-of-the-art Solution Center in São Paulo, Brazil
The initiative launched in 2019 has touched over 10,000 lives with 500+ screening camps and aims to double its reach in the next 2 years
The WHO has urged China to increase adoption of mRNA vaccines, given their high efficacy against variant strains.
Products offered on a not-for-profit basis to the 45 lower-income countries now include the full portfolio for which Pfizer has global rights.
This donation will allow the continuation of the cycle of vaccination for children foreseen within the national immunization program carried out by the Ministry of Public Health of Cuba
Through the new agreements, Cristal Therapeutics and McSAF will gain access to Lonza’s integrated bioconjugates offering and will be able to leverage Lonza’s expertise in developing and manufacturing bioconjugates
The top 15 Indian pharma players have continued to experience anaemic growth in the US market over the five years ended FY22
Subscribe To Our Newsletter & Stay Updated
_256_275.jpeg)
